FIP2 antibodies are immunological tools designed to detect Rab11 Family-Interacting Protein 2 (Rab11-FIP2), a multifunctional regulator of endosomal trafficking and epithelial cell polarity . These antibodies enable researchers to study Rab11-FIP2’s roles in membrane recycling, cancer progression, and cellular signaling through techniques like Western blotting (WB), immunohistochemistry (IHC), and immunoprecipitation (IP) . Rab11-FIP2 interacts with Rab11 GTPases and motor proteins like MYO5B, influencing processes such as transcytosis, epithelial-mesenchymal transition (EMT), and receptor trafficking .
Gastric Cancer (GC):
Rab11-FIP2 is downregulated in GC tissues and acts as a tumor suppressor by inhibiting proliferation and metastasis via the miR-192/215 axis . Conversely, hypoxia-induced Rab11-FIP2 overexpression promotes EMT and metastasis through EGFR internalization .
Antibodies validated these findings via IHC and siRNA knockdown in xenograft models .
Rab11-FIP2 regulates transcytosis by forming complexes with Rab11a and MYO5B. Dominant-negative mutants (e.g., Rab11-FIP2(ΔC2)) disrupt recycling endosome morphology, as shown via immunofluorescence and co-immunoprecipitation .
Rab11-FIP2 is hijacked by Chlamydia pneumoniae to avoid lysosomal degradation. Antibodies confirmed its recruitment to pathogen-containing inclusions .
FIP2 antibodies undergo rigorous validation:
Western Blot: Specificity confirmed by a single band at 58 kDa in human 293 and HeLa cell lysates .
Immunocytochemistry: Localization to recycling endosomes in MDCK and HEK-293 cells .
Functional Assays: siRNA knockdown rescues miR-192/215 inhibitor effects in GC xenografts .
Discrepant Findings: Rab11-FIP2’s role in cancer remains context-dependent, with both tumor-suppressive and pro-metastatic roles reported. Antibody specificity must be confirmed using knockout controls.
Cross-Reactivity: Some antibodies cross-react with Arabidopsis FIP2 , necessitating species-specific validation.